According to an article published in Science magazine in July, almost 100 SARS-CoV-2 vaccines are currently in clinical trials in various places around the world, but only seven are are delivered intranasally. Intranasal vaccines have a potential to do more to protect areas of infection in the nasal passages and upper airways. There may be issues effectiveness for people who have prior exposure to viruses the vaccines are based on.